Company analysis

Emerging Pharma
Big Pharma
Mid Pharma
Japan Pharma
Hot Topics
M&A Analysis

Text search

Sort by Name

Click to order products ascending

Display 15 Products per page

M&A Outlook 2018

$3,000.00

PharmaVitae explores the rationale for accelerated dealmaking in 2018, earmarking companies touted for M&A activity, and details 27 targets that potential acquirers should prioritize based on strategic themes, KOL interviews, and physician surveys.
April 24, 2018
Find out more
Mid Pharma Licensing and M&A Trends, 2011–16

$2,995.00

This analysis covers trends in alliance and mergers and acquisitions (M&A) agreements by Datamonitor Healthcare’s Mid Pharma peer set from 1 January 2011 through to 30 September 2016. Only deals involving drug discovery, development, or commercialization were considered for this analysis. All data were derived from Informa’s Strategic Transactions and Medtrack databases.
February 16, 2017
Find out more
Mid Pharma Outlook

$3,000.00

Total sales from the mid pharma peer set amounted to $69.4bn in 2011; by the end of 2012, this figure rose by 1.6% to $71.0bn. During 2012 the peer set constituents exhibited varying degrees of sales growth.
September 28, 2016
Find out more
Orphan Drug Market Outlook to 2017

$3,000.00

Tumbling over the patent cliff, many Big Pharma companies are being forced to find new strategies for sustaining sales growth, wherever possible minimizing the risk of generic competition.
September 28, 2016
Find out more
Pharma-Payer Partnerships in Emerging Markets

$2,995.00

Payer partnerships are becoming widespread as emerging markets become wealthier, but access challenges remain. Partnerships with proven success include “strategic philanthropy,” patient access programs, tiered pricing, and service support models.
July 26, 2017
Find out more
Q2 2016 Earnings Previews

$3,000.00

Datamonitor Healthcare previews Q2 2016 earnings for companies in the PharmaVitae portfolio. Companies will be continuously added the day before presentations.
September 28, 2016
Find out more
Regenerative Medicine Landscape

$2,995.00

The competitive landscape for regenerative medicine continues to evolve. As private sector investment in active players continues, efforts by governments in the US and EU are helping to advance the field, including the recent passage of the 21st Century Cures Act in the US, providing a special status pathway for regenerative medicine advanced therapies.
July 21, 2017
Find out more
Shire Company Analysis

$3,000.00

PharmaVitae explores Shire’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts
August 30, 2018
Find out more
Social Media in Pharma

$2,995.00

While social media is still relatively new, it has been heralded as one of the most significant changes in the way that people communicate with one another. Despite this, the pharmaceutical industry has been slow to become involved with social media, fearing compliance and regulatory breaches and preferring to stay with the more traditional routes of communication, such as representative visits and emails. However, the growing popularity of social media, combined with a number of positive examples from both within and outside the pharmaceutical industry, has led to an increasing number of pharmaceutical companies looking to grow their social media presence and build on the unique opportunities these platforms offer.
January 27, 2017
Find out more
The Latest in Immuno-Oncology: A Deep Dive into Non-Small Cell Lung Cancer (NSCLC)

$3,000.00

This decade has seen the emergence of therapies harnessing the immune system to treat cancer.
October 1, 2018
Find out more
Trends: Hot Topic Catalyst

$750.00

The FDA Amendments Act (FDAAA) provided the FDA with new powers in relation to drug safety, including the authority to impose postmarketing requirements (PMRs) and Risk Evaluation and Mitigation Strategies (REMS) on drug manufacturers.
November 19, 2020
Find out more
Under the Radar Takeover Targets

$3,000.00

Following on from its M&A Outlook 2018 report, PharmaVitae highlights under the radar takeover targets that are potentially attractive to companies on the prowl for acquisitions.
July 20, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *